VenatoRx Awarded NIH RO1 Grant

René Russo, PharmD, BCPS

René Russo, PharmD, BCPS

President and Chief Executive Officer

Arsanis, Inc.

René Russo, PharmD, BCPS, has spent more than 15 years in anti-infective R&D and has leadership experience across all phases of drug development, including global commercial launches for five novel antibacterial agents and clinical development and registration of several antiviral, antibacterial, and antifungal therapeutics. Her work has spanned the earliest phases of in vitro and animal work to clinical pharmacology, clinical development, and post-marketing clinical outcomes research. Prior to Arsanis, Dr. Russo served in various roles over an 11-year period at Cubist Pharmaceuticals (Cubist). As Vice President of an 80+ person global team, Dr. Russo oversaw the clinical microbiology program (including extensive in vitro and animal work to support dose selection and PK/PD analyses), contributed to the design of multiple Phase 1 to Phase 3 clinical studies, and directly managed the oversight of several global burden of disease programs, including urosepsis and nosocomial pneumonia, to understand the outcomes and unmet medical needs in these infectious diseases. In her role at Cubist, she was also responsible for the oversight of more than 140 studies designed to further understand Gram-positive and Gram-negative infections, including epidemiology, resistance patterns, and the study of various treatments (including combination therapies) across nonclinical and clinical studies. Dr. Russo directly oversaw investigator-initiated research for a broad portfolio of anti-infectives, including daptomycin, fidaxomicin, ceftolozane/tazobactam, and tedizolid. Prior to her time at Cubist, Dr. Russo held roles of increasing responsibility at Bristol-Myers Squibb where she started her industry career as a Postdoctoral Fellow in Industrial Pharmacy Infectious Diseases. She also held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital before joining the biotechnology industry. Dr. Russo received her PharmD and Bachelor of Science in Pharmacy from Rutgers University and holds a Board of Pharmacy Specialties Pharmacotherapy Certification (BCPS).

Roger J. Pomerantz, M.D., F.A.C.P.

Chief Executive Officer and Chairman of the Board

ContraFect Corporation

Dr. Pomerantz was appointed ContraFect’s Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors since May 2014. He currently serves as Chairman of the board of directors of Seres Therapeutics, and served as Chairman and CEO from June 2014 until January 2019. From 2011 to 2013, he was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed 12 drugs approved world-wide in important diseases, including HIV, HCV, CMV, and tuberculosis.

Christine Ann Miller

AWG Board Chair
President & CEO
Melinta Therapeutics

Christine Ann Miller has served as President and Chief Executive Officer and as a member of the board of Melinta Therapeutics since August 2020. Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. Most recently, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was accountable for transitioning the portfolio toward- rapid-growth and higher-margin segments, such as complex generics and value-added medicines, while continuing to build the branded generics business.

Among her various achievements, Ms. Miller directed more than 50 product launches that generated over $300 million of new annual revenue, closed numerous business development acquisitions, and built a robust five-year development and acquisition product pipeline. Before Sandoz, Ms. Miller spent over a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals where she led the preparation of numerous product launches and held leadership roles in both R&D operations and supply chain management. Ms. Miller started her career at Merck as a chemical engineer and procurement analyst and earned an MBA and a Master’s in Technology Management at Stevens Institute of Technology and a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute.

Ms. Miller’s leadership focus combines her passion for building and leading high performing teams with goal-driven operational rigor. She articulates a clear mission, vision and strategy that engages people to cohesively work towards creative problem solving and innovative solutions.

She serves as an Advisory Board Member for the Healthcare Businesswomen’s Association and is a frequent panelist and speaker at industry events.

Graham G. Lumsden

Chief Executive Officer

Motif BioSciences Inc

Graham G. Lumsden, Chief Executive Officer of Motif, is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining Motif, Mr. Lumsden was a senior executive at Merck & Co., Inc. where he held commercial leadership positions in worldwide businesses including contraceptives and osteoporosis. Mr. Lumsden has a proven record of success leading change and delivering results in subsidiary and global leadership positions, including new product launches, pre-clinical/clinical development, regulatory strategy, cross-functional team leadership, IP strategy/litigation, and domestic/international sales and marketing. Mr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a postgraduate diploma from the Chartered Institute of Marketing (MCIM), and is a dual citizen of the U.S. and UK.

Marco Taglietti, M.D.

Dr. Taglietti joined SCYNEXIS as Chief Executive Officer in April 2015 and has been a member of the board since November 2014. He became SCYNEXIS President in September 2015. He served as Executive Vice President, Research and Development, and Chief Medical Officer of Forest Laboratories, Inc. and as President of the Forest Research Institute until its acquisition by Actavis in 2014. Prior to joining Forest Laboratories, Inc. in 2007, Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc. for three years. He joined Stiefel Laboratories, Inc. after 12 years at Schering-Plough Corporation where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. Dr. Taglietti currently serves on the Board of Directors of NephroGenex, Inc. (NASDAQ:NRX) and Delcath (NASDAQ:DCTH). He received his medical degree and board certifications from the University of Pavia in Italy.

Ankit Mahadevia

Chief Executive Officer

Spero Therapeutics

Ankit Mahadevia is the Chief Executive Officer of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, MA. In that capacity he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, three of which he led as Acting CEO. Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).

Jeffrey Stein, Ph.D.

President and Chief Executive Officer
Cidara Therapeutics

Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director of Paratek Pharmaceuticals (NASDAQ: PRTK) and Ideaya Biosciences. He is also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.

Evan Loh, M.D.

Chair, AWG Chemistry, Manufacturing
and Controls(CMC) Subcommittee
Chief Executive Officer
Paratek Pharmaceuticals, Inc

Evan Loh, M.D. is the Chief Executive Officer of Paratek Pharmaceutical since June 2019. Prior to that, Dr. Loh served as Chief Operating Officer from January 2017 to June 2019 and as President and Chief Medical Officer from July 2014, in each case until June 2019. He is a member of the Board of Directors since July 2014. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh was appointed President in June 2014 and served as Chief Medical Officer and Chairman of the Board of Directors from June 2012 to June 2014. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas where he was responsible for global development strategy and clinical operational deliverables. At Wyeth, he led the successful global registration programs for Torisel and Tygacil. He currently serves on the Board of Directors of Eiger Biopharmaceuticals, Inc. and as Chair of the Antimicrobials Working Group, an industry leading organization of biotech companies focused on antimicrobial development. Dr. Loh served as a director on the Board of Nivalis from 2012 until the completion of its sale to Alpine Immunotherapeutics in 2017. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.

Michael Dunne, M.D

AWG Vice Chair

Chief Scientific Officer

Iterum Therapeutics

Michael Dunne, M.D. has served as Chief Scientific Officer of Iterum Therapeutics since late 2015 when the company was formed. Prior to that, Dr. Dunne was the Chief Medical Officer of Durata Therapeutics, Inc. from 2009 until its acquisition by Actavis plc in 2014 and remained in a leadership role as part of the Actavis integration efforts to ensure successful transition of all priority development activities until 2015. From 1992 to 2009, Dr. Dunne served in a variety of roles in connection with the clinical development of numerous infectious disease compounds at Pfizer Inc., including as the Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. Dr. Dunne holds a BA in Economics from Northwestern University and an MD from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.

Ciara Kennedy, Ph.D.

Ciara Kennedy, Ph.D., is President and CEO of Amplyx Pharmaceuticals, Inc. Initially, Ciara Kennedy was appointed Chief Operating Officer of Amplyx in October 2015, following a successful, $50 million Series B financing. Prior to joining Amplyx, Dr. Kennedy served as Chief Operating Officer at Lumena Pharmaceuticals until the company was acquired by Shire Pharmaceuticals in June 2014; she remained with Shire for one year post-acquisition as Vice President and Head of the Cholestatic Liver Disease Program. As COO of Lumena, Dr. Kennedy played a critical role in the development of assets licensed from Pfizer and Sanofi, raising $78M from venture capital to fund operations and preparing to take the company public. Ciara has a proven track record of delivering significant results and advancing therapeutic and diagnostic programs across multiple therapeutic areas and stages of development in the biotechnology industry. Prior to Lumena, she was Vice President of Operations and Senior Director of Strategy and Corporate Development at Cypress Bioscience Inc., where she played a key role in obtaining FDA approval for Savella, a therapy for fibromyalgia, and also oversaw corporate acquisitions and in-licensing of several clinical assets. Previously, Dr. Kennedy held several positions in the Program and Alliance department of Biogen Idec, managing projects spanning the drug discovery and development continuum. Dr. Kennedy received her doctorate at the Queen’s University of Belfast, Northern Ireland, and continued her research in the field of apoptotic proteases at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. In 2004, she became a member of the inaugural class of the Rady School of Management at University of California, San Diego. She graduated with a Masters of Business Administration in 2006.

Ted Schroeder

Chief Executive Officer
Nabriva Therapeutics

Ted Schroeder joined Nabriva Therapeutics plc in July 2018. During the last 30 years, he has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, Ted served as president, chief executive officer and director of Zavante Therapeutics until its acquisition by Nabriva Therapeutics in 2018. Ted co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics (Nasdaq: CDTX), Otonomy (Nasdaq: OTIC) and Collegium Pharmaceutical (Nasdaq: COLL). He is a former chair of BIOCOM, the Southern California life sciences trade association and in 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.

Kevin Finney

Chief Operating Officer

Zavante Therapeutics

Kevin P. Finney currently serves as Chief Operating Officer of Zavante Therapeutics. Finney has over 20 years of healthcare leadership experience spanning early stages of development and commercialized brands for pharmaceutical, medical device and diagnostic segments. Finney recently served as Vice President and Head of Corporate Development at Allergan, with responsibility for world-wide corporate development strategy, licensing, acquisitions and alliances. Finney held this position through the successful $71 billion acquisition of Allergan by Actavis in March 2015. In his previous tenure at Allergan, the company grew from less than $3 billion in annual revenue to more than $7 billion through a combination of acquisitions and organic growth. Before this, Finney held commercial executive management roles at Prometheus Laboratories, Inc. (now NestleHealthScience), Amylin Pharmaceuticals, Inc. (now Bristol-Meyers Squibb) and Parke-Davis division of Warner-Lambert (now Pfizer). Mr. Finney currently serves on the board of Taris Biomedical and Eirion Therapeutics. Finney received master’s degree in business from Pepperdine University and a bachelor’s degree in exercise physiology from California State University, Long Beach.

Manos Perros, Ph.D.

AWG Vice Chair
Chief Executive Officer, co-Founder and Director
Entasis Therapeutics

Manos Perros, Ph.D., has served as Chief Executive Officer, co-founder and Director of Entasis Therapeutics since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as Vice President and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as Director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as Vice-President and Chief Scientific Officer, Antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an Associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer’s Award in 2010.

David Roblin

Chief Operating Officer, Chief Medical Officer & President of R&D
Summit Therapeutics plc

David Roblin has served as Summit’s Chief Operating Officer, Chief Medical Officer and President of Research and Development since May 2017. Dr. Roblin acted as a research and development adviser to Summit from 2014. Dr. Roblin has served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London from 2014 to 2017. Prior to that, Dr. Roblin was Head of Research, Site Director and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999. After Dr. Roblin left Pfizer Inc. in 2011, he held a variety of board and advisory positions as well as Chief Medical Officer to biotechnology companies including Creabilis SA until 2014. Dr Roblin has a degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital. He is a Fellow of the Royal College of Physicians, a Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s. He remains as Chair of the Crick Translation Advisory Group and also serves on the BioMedical Catalyst Board Major Awards Committee, the Wellcome’s Science Innovation Translation Advisory Group and the scientific advisory groups for the LEO Foundation and Destiny Pharma PLC. He is also a member of the board of directors of Sosei. Before entering the life sciences industry, Dr Roblin practiced medicine for five years.

Stephen Conafay

AWG Washington Counsel

Steve Conafay has 35 years of leadership and management experience in government relations, public policy and communications. As the sole principal at The Conafay Group, he oversees all client servicing. While leader of the bio-life science practice at Fabiani & Company, he oversaw more than $810 million in non-dilutive financing awarded to the team’s clients. For 12 years, Mr. Conafay was vice president of government relations for Pfizer, where he was elected as a corporate officer in 1984. He served as senior vice president of corporate affairs for Glaxo Inc., where he was also a member of the Board of Directors. After heading the legislative practice for Jones, Day, Reavis and Pogue, the world’s second largest law firm, he was tapped by the Pharmaceutical Research and Manufacturers of America (PhRMA) to assume the No. 2 position of executive vice president of strategic and legislative affairs. He also served as an executive fellow at the American Enterprise Institute, the leading free market think tank in the U.S. After moving to the New York area, Mr. Conafay joined Shandwick, where he assumed several positions of increasing responsibility, culminating with his appointment as chief executive officer for The Americas-East in 2000.

Mr. Conafay is a lawyer and a decorated Vietnam veteran. He served as an infantry platoon leader and was awarded the Silver Star, Bronze Star with Oak Leaf Cluster, the Air Medal and the Army Commendation Medal, among others. He is also an avid golfer and has been a member of Congressional Country Club for more than 30 years. Mr. Conafay is a lifelong fan of the New York and San Francisco Giants. In his 60s, he ran and completed four Army 10-miler races, and plans to continue competing in his 70s.

Christopher J. Burns, Ph.D.

Founder, President and Chief Executive Officer
Venatorx Pharmaceuticals, Inc.

Dr. Burns has more than 25 years of corporate and research and development experience within both major and specialty pharmaceutical companies. At VenatoRx Pharmaceuticals, Dr. Burns has developed a comprehensive USG/NGO financing strategy that has enabled the Company to build out a world-class antibacterials portfolio. Prior to VenatoRx, Dr. Burns served as a member of the Executive Management Team and as Vice President of Research at Protez Pharmaceuticals through its acquisition by Novartis in 2008. Prior to Protez/Novartis, Dr. Burns served as Director of Chemistry at ViroPharma, producing clinical candidates for Hepatitis C (HCV-796) and smallpox infections (Tecovirimat, licensed to and developed by Siga Technologies). Prior to this, Dr. Burns served as a core member of the Global Lead Optimization Counsel at Rhone-Poulenc Rorer/Aventis. During his 12 years at RPR/Aventis, Dr. Burns led multidisciplinary teams in bone metabolism, cardiovascular disease (in the U.S.), and oncology (in France). Dr. Burns has appeared as co-author or co-inventor on more than 60 patents and publications and has served as Principal Investigator on more than 10 awarded U.S. National Institute of Health (NIH) grants. He received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT) under Nobel-laureate Professor K. Barry Sharpless. He currently serves on the Board of Directors at Life Sciences Pennsylvania (LSPA) and the Antimicrobials Working Group (AWG). .

Michael N. Dudley, Pharm.D.

President and Chief Executive Officer
Qpex Biopharma, Inc.

Dr. Dudley has over 30 years of experience in antiinfective drug research, development, and commercialization. In 2018, he co-founded Qpex Biopharma which raised $33M in Series A financing and acquired the preclinical infectious disease programs from The Medicines Company. He has overseen the development and regulatory approval of 3 antibiotics, most recently a beta-lactamase inhibitor combination product from a new chemical class (vaborbactam) discovered in the company laboratories. The antibiotic product Vabomere™ advanced from discovery to FDA approval in 2017 in less than 8 years. He lead the negotiation for multiple contracts from public-private partnerships (e.g., BARDA of the US Government; Innovative Medicines Initiative for the EU) for a combined total of over $190 million funding to advance antimicrobial agents in development in the US and Europe. Prior to co-founding Qpex, he was Chief Scientific Officer and co-founder of Rempex Pharmaceuticals that was acquired by the Medicines Company (MDCO) in 2013, where he remained as the co-leader of the Infectious Disease Business Unit of MDCO. Prior to Rempex, he held VP/SVP/CSO positions of increasing responsibility at the biotech companies Mpex Pharmaceuticals (acquired by Aptalis in 2011), Diversa Corporation, and Microcide Pharmaceuticals. Prior to his career in pharmaceutical industry, he held full-time academic appointments that included Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and Adjunct Professor of Medicine, Brown University School of Medicine at Roger Williams Medical Center in Providence, RI. As an academic researcher, he conducted preclinical and clinical research in antibacterial, antifungal, and antiviral agents, including pioneering work on PK-PD approaches for several classes of antiinfectives. Dr. Dudley has published over 130 scientific papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA and EMA workshops, international meetings on infectious diseases, and advisor to several companies. He has served as an Editor for the journal Antimicrobial Agents and Chemotherapy and numerous other editorial and advisory boards. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (PharmD) from the University of California San Francisco (UCSF), completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.

Ramani Varanasi

Ms. Varanasi is a co-founder, President and CEO of X-Biotix. She is an accomplished business executive, with 24 years of biopharmaceutical industry experience and a distinguished track record in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organizations. She has held Research and senior level positions in Business & Corporate Development including at Merck, Millennium (now Takeda), Momenta, and Checkmate Pharmaceuticals, to name a few. Over the course of her career, Ramani has been involved in the formation of strategic partnerships with companies and research organizations globally, including in emerging markets such as Asia - and continues to have a keen interest in bridging the research and business gap and fostering collaboration between enterprises in this global marketplace. Her broad experience in the areas of early stage company formation and financing, including dilutive and non-diluting funding initiatives, has enabled her to execute deals with total value in excess of several billion dollars. Ramani holds a B.Sc. and a M.Sc. from McGill University in Microbiology & Immunology and Biochemistry, respectfully, and an MBA in General Strategy from Northeastern University. She volunteers as a mentor to start-up companies in the biopharma area and also has an avid interest in the area of international healthcare, a sector in which she has been involved as a board member for two non-profit organizations.

Corey Fishman

Chief Executive Officer
Iterum Therapeutics

Corey Fishman is a founder of and has served as Chief Executive Officer of Iterum Therapeutics since its formation in late 2015. From 2010 to 2015, Mr. Fishman served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. overseeing all aspects of finance and administration, manufacturing, business development, strategy, international operations and portfolio optimization. While at Durata, he raised substantial capital, including a successful IPO and secondary public offering. Mr. Fishman also led the negotiation and sale of the company to Actavis plc. Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus company from 2008 to 2010. From 2002 to 2008, Mr. Fishman served in a leadership role at MedPointe Healthcare, Inc., a private equity backed specialty pharmaceutical company and became the Chief Financial Officer in 2006. Mr. Fishman had responsibility for finance and administration, portfolio optimization, manufacturing, strategy and business development. He led the development and implementation of a new strategic plan, which involved raising capital, restructuring debt, accelerating the growth of existing commercial assets and developing multiple line extensions to enhance future value, culminating in the successful sale of the company to Meda AB. From 1994 to 2002, Mr. Fishman held roles of increasing responsibility in both mid-size and large pharma.

Mr. Fishman was a Director of Momenta Pharmaceuticals (MNTA) and BioSpecifics Technology Corporation (Nasdaq: BSTC), until both companies were acquired late in 2020.

Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University.

Felix Faupel

Chief Commercial Officer, Bacthera

Felix was appointed as Chief Commercial Officer of Bacthera in September 2020. Before he was leading the Contract Manufacturing business of the generics company Acino International AG. He initially joined Acino as Global Key Account Manager in 2016. Before, he was working as a Business Development Manager for the tech-consulting company Altran (now part of Capgemini) and for the peptide API CDMO Bachem. Felix studied at the University of Zurich (UZH) and holds a Master of Science in Chemistry and Business Studies.

Adrian Nivoliez

Chief Executive Officer, Biose

Adrien heads up Biose industrie. He has worked for several years at Biose with quality, production and global R&D positions. Adrian has completed his studies at the Université Paris-Sud, his PhD in Medical Microbiology and bacteriology at the University Blaise Pascal and has also an executive MBA from the European Institute of Technology (EPITECH). A major part of his research has been focused on the manufacturing impact on Live Biotherapeutic Product potencies.